298 research outputs found
Trajectory-based worker task productivity monitoring
Over the past decades labour productivity in construction has been declining. The prevalent approach to estimating labour productivity is through an analysis of the trajectories of the construction entities. This analysis typically exploits four types of trajectory data: a) walking path trajectories, b) dense trajectories (posture), c) physiological rates such as heart rate (beats/minute) and respiratory rate (breaths/minute), and d) sound signals. The output of this analysis is the number of work cycles performed by construction workers. The total duration of these cycles is equal to the labour input of a task. However, all such methods do not meet the requirements for proactive monitoring of labour productivity in an accurate, non-obtrusive, time and cost efficient way for multiple workers. This paper proposes a method to address this shortcoming. It features a promising accuracy in terms of calculating the labour input.ICASE studentship award, supported by EPSRC and LAING O'ROURKE PLC under Grant No. 13440016
Recommended from our members
Prioritising Object Types of Industrial Facilities to Reduce As-Is Modelling Time
The cost of modelling existing industrial facilities is currently considered to counteract the benefits of the model in managing and retrofitting the facility. 90% of the modelling cost is typically spent on labour for converting point cloud data to the final model, hence reducing the cost is only possible by automating this step. Previous research has successfully validated methods for modelling specific object types such as pipes. Yet modelling is still prohibitively expensive. We tackle a part of this issue by identifying the most frequent object types that require modelling in industrial plants to guide future work aimed at automating the tedious current practice. We determine a priority list of the object types in these facilities based on their frequency of appearance (%) and intent of modelling. A parametric study based on Outer Diameter (OD) then finds the most frequent OD ranges for these objects. The results indicated that steel sections were the most frequent object type encountered in all case studies
Recommended from our members
What Objects are Most Important when Modelling Existing Industrial Facilities?
The cost of modelling existing industrial facilities currently counteracts the benefits these models provide for maintenance and retrofit of these assets. 90% of the modelling cost is spent on labor for converting point cloud data to 3D models, hence reducing the cost is only possible by automating this step. The highly-cluttered scene and large number of industrial objects increase the required modelling time. Therefore, modelling is prohibitively expensive. We tackle a part of this issue by identifying the most frequent object categories and object types that
require modelling in industrial plants to guide future work aimed at automating the tedious current practice. The industrial facilities investigated are: (a) offshore platforms, (b) food processing facilities and (c) petrochemical plants. The industrial object types obtained from BIM models are hierarchically ordered based on their frequency of appearance and modelling intent. The results showed that structural elements, the piping system and electrical equipment were the most frequent object categories encountered in all case studies. The most frequent object types in these categories are then determined by implementing a statistical analysis on their frequency of appearance in all case studies. The modelling intent of the most frequent object types in these categories is then explored to determine the most important object types. These are in descending order: electrical conduit, straight pipes, circular hollow sections, elbows, channels, solid bars, I-beams, angles and flanges. Automatically modelling these frequent and critical object types can guide future researchers interested in modelling these assets
Outcomes with Orbital and Rotational Atherectomy for Inpatient Percutaneous Coronary Intervention
INTRODUCTION: Our objective was to describe the contemporary outcomes of orbital atherectomy (OA) vs. rotational atherectomy (RA) use for inpatient percutaneous coronary intervention (PCI) in the United States. Data on the use of OA vs. RA in contemporary inpatient PCI are limited.
METHODS: We queried the Nationwide Readmission Database (NRD) from January to November for the years 2016-2017 to identify hospitalizations of patients who underwent PCI with atherectomy. We conducted a multivariate regression analysis to identify variables associated with in-hospital mortality.
RESULTS: We included 77,040 records of patients who underwent inpatient PCI with atherectomy. Of those, 71,610 (93%) had RA, and 5430 (7%) had OA. There was no significant change in the trend of using OA or RA over 2016 and 2017. OA was less utilized in patients presenting with ST-segment elevation myocardial infarction (STEMI) (4.3% vs. 46.8%, p \u3c 0.001). In our cohort, OA was associated with lower in-hospital mortality (3.1% vs. 5%, p \u3c 0.001) and 30-day urgent readmission (\u3c 0.01% vs. 0.2%, p = 0.009), but a higher risk of coronary perforation (1.7% vs. 0.6%, p \u3c 0.001) and cardiac tamponade (1% vs. 0.3%, p \u3c 0.001) and a higher cost of index hospitalization (23,188, p \u3c 0.001) compared with RA.
CONCLUSION: RA remains the predominant atherectomy modality for inpatient PCI in the United States (93%). There was no change in the trend of use for either modality over the years 2016 and 2017. OA was noted to have a lower incidence of in-hospital death, but a higher risk of coronary perforation and a higher cost of index hospitalization for the overall unmatched cohorts
TCT-319 Use of Limited Antegrade Subintimal Tracking Technique in Chronic Total Occlusion Percutaneous Coronary Intervention
Background: There are limited data on the limited antegrade subintimal tracking (LAST) crossing technique for chronic total occlusion (CTO) percutaneous coronary intervention (PCI).
Methods: We analyzed the frequency of use and outcomes of LAST among 2,003 CTO PCIs performed with antegrade dissection and re-entry (ADR) in the PROGRESS-CTO Registry between 2012 and 2021 at 39 centers.
Results: LAST was used in 144 cases (7.2%), primary LAST in 113 (5.6%), and secondary LAST in 31 cases (1.5%). The Stingray system was used in 905 cases (45.2%), subintimal tracking and re-entry (STAR) in 333 cases (16.6%), and contrast-guided STAR in 29 cases (1.4%). The mean patient age was 64.2 ± 10 years, 86% were men, and 34.9% had prior coronary artery bypass graft surgery. Cases in which LAST was used were less complex with a lower J-CTO score (2.50 ± 1.32 vs. 2.95 ± 1.10, P \u3c 0.001). There was no difference in technical (75.0% vs 78.4%, P = 0.337) and procedural success (72.2% vs 75.5%, P = 0.384) and major cardiac adverse events (MACEs) (2.08% vs 3.55%, P = 0.352) between LAST and non-LAST cases. However, cases in which the LAST technique was used required less procedure and fluoroscopy time (Figure 1A). A primary LAST technique was associated with higher technical and procedural success rates and a similar MACE rate compared with a secondary LAST technique (Figure 1B).
Conclusion: LAST is used in 7.2% of ADR CTO PCI cases and is associated with similar technical and procedural success rates and major complication rates but lower procedural and fluoroscopy time compared with ADR cases that did not use LAST
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial
IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measurewas a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95%CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95%CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246. Copyright 2014 American Medical Association. All rights reserved
Artificial Intelligence, Computational Simulations, and Extended Reality in Cardiovascular Interventions
Artificial intelligence, computational simulations, and extended reality, among other 21st century computational technologies, are changing the health care system. To collectively highlight the most recent advances and benefits of artificial intelligence, computational simulations, and extended reality in cardiovascular therapies, we coined the abbreviation AISER. The review particularly focuses on the following applications of AISER: 1) preprocedural planning and clinical decision making; 2) virtual clinical trials, and cardiovascular device research, development, and regulatory approval; and 3) education and training of interventional health care professionals and medical technology innovators. We also discuss the obstacles and constraints associated with the application of AISER technologies, as well as the proposed solutions. Interventional health care professionals, computer scientists, biomedical engineers, experts in bioinformatics and visualization, the device industry, ethics committees, and regulatory agencies are expected to streamline the use of AISER technologies in cardiovascular interventions and medicine in general
The role of intravascular imaging in chronic total occlusion percutaneous coronary intervention
Chronic total occlusions (CTOs) represent the most complex subset of coronary artery disease and therefore careful planning of CTO percutaneous coronary recanalization (PCI) strategy is of paramount importance aiming to achieve procedural success, and improve patient's safety and post CTO PCI outcomes. Intravascular imaging has an essential role in facilitating CTO PCΙ. First, intravascular ultrasound (IVUS), due to its higher penetration depth compared to optical coherence tomography (OCT), and the additional capacity of real-time imaging without need for contrast injection is considered the preferred imaging modality for CTO PCI. Secondly, IVUS can be used to resolve proximal cap ambiguity, facilitate wire re-entry when dissection and re-entry strategies are applied and most importantly to guide stent deployment and optimization post implantation. The role of OCT during CTO PCI is currently limited to stent sizing and optimization, however, due to its high spatial resolution, OCT is ideal for detecting stent edge dissections and strut malapposition. In this review, we describe the use of intravascular imaging for lesion crossing, plaque characterization and wire tracking, extra- or intra-plaque, and stent sizing and optimization during CTO PCI and summarize the findings of the major studies in this field
- …